Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Linagliptin/Metformin FDC vs Free Combination
NCT02173639Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2009
- Primary completion
- Jun 2009
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of linagliptin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of BI 1356 in plasma over the time interval from 0 to 72 h, Maximum measured concentration of the analyte in plasma up to 168 hours and 1 more. Started Apr 2009; status: completed.
02
Drugs
linagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02173639.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02173639.